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Background/Purpose: This study examined the psychometric properties and clinical 
validity of the EORTC QLQ-PR25, a questionnaire for assessing the quality of life of 
patients with prostate cancer.
Methods: The Taiwan Chinese version of the prostate cancer module (EORTC 
QLQ-PR25) and the core questionnaires (EORTC QLQ-C30) were administered to 81 
patients with prostate cancer after they had been treated with surgery or hormone 
therapy or both. The QLQ-PR25 module assesses urinary symptoms, bowel symp-
toms, hormonal treatment-related symptoms, sexual activity and sexual functioning.
Results: The questionnaires were well accepted by the patients and very few of the 
items had missing data. Only the urinary symptom scale showed satisfactory inter-
nal consistency. Scales were able to differentiate clinical groups of patients with corre-
sponding symptoms, but the differences were smaller than that of major functioning 
scales in the core questionnaire.
Conclusion: The Taiwan Chinese version of the EORTC QLQ-PR25 is acceptable in 
patients with prostate cancer in Taiwan, able to differentiate corresponding symp-
toms, but the scale structure needs further improvement.
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1.  Introduction
Prostate cancer is one of the most common cancers in 
men in Western countries and developed Asian coun-
tries.1,2 Along with a rapidly aging population and west-
ernized dietary habits, the incidence and mortality of 
prostate cancer in Taiwan have increased rapidly in the 
last few decades. The age-adjusted incidence (adjusted 
by the 1976 world population) has risen from 1.86 per 
100,000 men in 1979 to 18.40 per 100,000 men in 2006.3 
The age-adjusted mortality rate of prostate cancer has 
risen from 2.3 per 100,000 men in 1986 to 6.7 per 
100,000 men in 2007. This cancer is now the seventh 
leading cause of cancer death in men in Taiwan.3,4
Prostate cancer has relatively good prognosis among 
cancers. The 5-year survival rate can reach 70%.1,5 The 
long survival means that quality of life (QoL) is an impor-
tant indicator of treatment success in survivors. Among 
the various treatment modalities of surgery, radiother-
apy, hormone therapy and chemotherapy, survival rates 
do not differ too much, but the adverse effects do.5–8 
Surgery affects sexual function and may cause stress uri-
nary incontinence. Radiotherapy may induce irritative 
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voiding symptoms and gastrointestinal symptoms.9 There-
fore, QoL may differ after different treatments. It is neces-
sary to develop a disease-specific instrument to measure 
these problems in patients with prostate cancer who un-
dergo different treatments.
Among the randomized controlled trials of QoL of 
patients with prostate cancer between 1980 and 2001, 
the EORTC QLQ-C30 developed by the European Organisa-
tion for Research and Treatment of Cancer (EORTC) was 
the most commonly used instrument.10 However, the 
specific problems of patients with prostate cancer are 
not covered. The EORTC established guidelines for sup-
plementary module development in 1993.11 For assess-
ing the issues of QoL of patients with prostate cancer, 
the EORTC developed a supplementary module, the EORTC 
QLQ-PR2512 according to the guidelines, which is com-
prised of 25 questions that cover 6 scales: PR URI (uri-
nary symptoms, 8 items); PR AID (incontinence aid, 1 
item); PR BOW (bowel symptoms, 4 items); PR HTR (hor-
monal treatment-related symptoms, 6 items); PR SAC 
(sexual active, 2 items); and PR SFU (sexual function, 4 
items). Five items are conditional questions, conditioned 
on the need of incontinence aid (Q37, PR7), and the sta-
tus of being sexually active (Q52–55, PR22–25). The re-
sults of international field validation published in 200813 
and validation studies of the EORTC QLQ-C30 and PR25 
in Spain published in 200814 and 200915 showed that the 
new instrument had acceptable psychometric proper-
ties, reliability and validity.
We obtained permission to translate and use the 
questionnaire from the EORTC and questionnaire devel-
oper with the agreement that we submit our results after 
the main international results have been published and 
that we follow EORTC guidelines for translation and pilot 
testing.16 In the past few years, we have published local 
validation results for the EORTC QLQ-C30 for head and 
neck, breast and lung cancers, and briefly reported the 
part of the C30 in stomach cancer.17–20 The aim of this 
study was to test the psychometric properties and clini-
cal validity of the Taiwan Chinese version of the EORTC 
QLQ-PR25 in a medical center in Taipei.
2.  Patients and Methods
2.1.  Patients
Patients with histologically confirmed prostate cancer, 
who were cared for and followed-up by one of the au-
thors (HJY) at the Department of Urology, National 
Taiwan University Hospital, between September 2004 
and September 2005, who were able to understand and 
answer the questions in the questionnaires, and willing 
to sign informed consent forms, were invited to partici-
pate in the study. Patients who had other malignancies, 
whose life expectancies were less than 3 months, or who 
were participating in other QoL studies that may affect 
the results of this study, were excluded. There was no limi-
tation in age and performance status, or special prefer-
ence in the recruitment process. The study was approved 
by the ethics committee of the study hospital.
2.2.  Questionnaires and data collection
All patients were invited to complete the Taiwan Chinese 
version of the EORTC QLQ-C30 (version 3.0) and the 
EORTC QLQ-PR25. We also collected patients’ comments 
regarding the time needed to complete the question-
naires, any help required during completion, and any 
questions that were confusing, difficult to answer or up-
setting. Patients’ demographic characteristics were col-
lected during the interview. Patients’ clinical information 
was collected by medical record review.
2.3.  Statistical analyses
We described the distribution of demographic and clini-
cal characteristics and answers of each question. The 
scores for each scale of the EORTC QLQ-C30 were calcu-
lated according to the scoring manual21 and the devel-
oper’s instructions. Cronbach’s α coefficient was used to 
evaluate the internal consistency of each scale. Multi-
trait scaling analyses were used to evaluate convergent 
validity and the item discriminant validity of each item 
in each scale. We also assessed the convergent and dis-
criminant validity of the EORTC QLQ-PR25 and the EORTC 
QLQ-C30 by examining the correlation coefficients of 
the scales of the two questionnaires. The clinical validity 
of each scale was examined by known-groups compari-
son among different groups of patients with different dis-
ease progression and treatments. Non-parametric methods, 
including Wilcoxon’s rank sum test and Kruskal-Wallis 
test, were used because of the non-normality of most 
scales. SAS version 9.1 (SAS Institute, Cary, NC, USA) was 
used. A p value of less than 0.05 was considered statisti-
cally significant.
3.  Results
We successfully recruited 81 patients; 59 (72.8%) were in 
the early stages (I or II) of the disease. Age, educational 
level, employment status, marital status and living ar-
rangements did not differ between early- and advanced-
stage patients, but patients with advanced disease had 
higher Gleason scores, more combined therapies, and 
partial prostatectomy (Table 1).
All patients completed the two questionnaires. The 
acceptability of the questionnaires was high. Most pa-
tients could complete the questionnaires in 15–30 min-
utes without help or only with help with reading the 
questions. There were no comments about wording and 
very few missing answers except on the conditional 
questions. There were no missing answers in the EORTC 
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QLQ-C30. In contrast, only 10 of the 20 unconditional 
questions on the EORTC QLQ-PR25 had no missing an-
swers. Most patients could understand the language of 
the questionnaire and complete the questionnaire by 
themselves. One Japanese patient needed some help 
with answering the questions.
Descriptive statistics of the answers to each question 
are shown in Table 2. Floor effects were seen for most 
questions, especially for Q37 (PR7, pain when urinating), 
Q41 (PR11, stool incontinence) and Q47 (PR17, weight loss).
In the analysis of internal consistency, only the 
Cronbach’s α coefficient of urinary symptoms reached a 
satisfactory level (0.80). The Cronbach’s α coefficients of 
bowel symptoms, hormonal treatment-related symptoms, 
and sexual activity were 0.41, 0.45, and 0.64, respec-
tively (Table 3). The internal consistency for sexual func-
tioning was not examined because of the high number of 
missing answers to conditional questions. The result of 
multi-trait scaling analysis of each scale corresponded 
well with internal consistency. Items whose item-to-own 
scale correlation was less than 0.40 included PR3 (Q33) 
urinary urgency, PR6 (Q36) incontinence, and PR7 (Q37) 
pain of urinary symptoms, all items of bowel symptoms 
(PR10–13, Q40–43), and all items of hormonal treatment-
related symptoms (PR14–19, Q44–49). All these items did 
not have any significantly higher correlation with other 
scales.
Most correlation coefficients between scales of the 
EORTC QLQ-PR25 and the EORTC QLQ-C30 were be-
tween 0.40 and 0.70 (moderately correlated), while 
some were even less than 0.40 (weakly correlated). Only 
the correlation for bowel symptoms and emotional 
functioning was greater than 0.70 (highly correlated) 
(Table 4).
In the known-groups comparison for clinical validity, 
we compared the QoL scores of patients with different 
clinical conditions. The scales in the core questionnaire 
(C30) were more discriminative than those in the PR25. 
Patients with advanced disease had poorer physical, role 
and social functioning, more fatigue, pain, nausea/vom-
iting, appetite loss and financial difficulty (the EORTC 
QLQ-C30), and more hormonal treatment-related symp-
toms and lower sexual activity (the EORTC QLQ-PR25) 
than those with early-stage disease. Only the differences 
in physical functioning, fatigue and pain were highly sig-
nificant (p < 0.01) (Table 5). Patients who had hormonal 
therapy had poorer physical functioning, more constipation 
Table 1  Sociodemographic and clinical characteristics of 
the 81 patients*
 Early disease Advanced disease
 stages (I, II) stages (III, IV)
 (n = 59) (n = 22)
Age (yr)  
 < 60 0 (0.0) 1 (4.6)
 60–70 17 (28.8) 3 (13.6)
 70–80 27 (45.8) 12 (54.6)
  > 80 15 (25.4) 6 (27.3)
Education
 Below primary 2 (3.4) 1 (4.6)
 Primary 5 (8.5) 7 (31.8)
 Junior high 5 (8.5) 3 (13.6)
 Senior high 10 (17.0) 2 (9.1)
 College (below 21 (35.6) 4 (18.2)
  university)
 University 8 (13.6) 4 (18.2)
 Graduate 4 (6.8) 1 (4.6)
 Missing data 4 (6.8) 0 (0.0)
Occupation
 Full-time 15 (25.4) 6 (27.3)
 Retired 20 (33.9) 7 (31.8)
 Unemployed 20 (33.9) 9 (40.9)
 Missing data 4 (6.8) 0 (0.0)
Marital status
 Married/cohabiting 52 (88.1) 18 (81.8)
 Single 0 (0.0) 1 (4.6)
 Widowed 3 (5.1) 3 (13.6)
 Missing data 4 (6.8) 0 (0.0)
Habitation
 With family 52 (88.1) 19 (86.4)
 Alone 3 (5.1) 3 (13.6)
 Missing data 4 (6.8) 0 (0.0)
Gleason score
  2 1 (1.7) 0 (0.0)
  3 3 (5.1) 0 (0.0)
  4 3 (5.1) 1 (4.6)
  5 9 (15.3) 0 (0.0)
  6 10 (17.0) 0 (0.0)
  7 24 (40.7) 8 (40.0)
  8 2 (3.4) 3 (13.6)
  9 4 (6.8) 7 (31.8)
 10 0 (0.0) 2 (9.1)
 Missing data 3 (1.7) 1 (4.6)
Treatment
 Observation 1 (1.7) 0 (0.0)
 Surgery 27 (45.8) 2 (9.1)
 Hormonal 10 (17.0) 2 (9.1)
 Surgery and 21 (35.6) 18 (81.8)
  hormonal
Prostatectomy
 No 10 (17.0) 2 (9.1)
 Radical 39 (66.1) 11 (50.0)
 Partial 10 (17.0) 9 (40.9)
(Contd)
Hormonal therapy
 No 28 (47.5) 2 (9.1)
 Yes 31 (52.5) 20 (90.9)
Active treatment
 No 23 (39.0) 3 (13.6)
 Yes 36 (61.0) 19 (86.4)
*Data presented as n (%).
QoL of prostate cancer patients
Vol. 21, 118–125, September 2010 121
Table 2 Mean, standard deviation, prevalence and missing data of each item of the EORTC QLQ-PR25
Item N Mean Standard deviation Prevalence (%) Missing data (%)
PR1: frequency/day 80 1.93 0.79 68.8 1.2
PR2: frequency/night 81 2.01 0.73 76.5 0.0
PR3: urgency 81 1.95 0.71 75.3 0.0
PR4: inadequate sleep 81 1.84 0.80 63.0 0.0
PR5: difficulty going out 81 1.56 0.79 39.5 0.0
PR6: urinary incontinence 81 1.64 0.66 55.6 0.0
PR7: pain when urinating 81 1.09 0.32  7.4 0.0
PR8: incontinence aid 21 1.71 0.96 47.6 74.7*
PR9: activity limited urinary 80 1.39 0.70 28.8 1.2
PR10: activity limited bowel 80 1.25 0.58 19.8 1.2
PR11: stool incontinence 80 1.05 0.22  5.0 1.2
PR12: blood in stools 79 1.13 0.43 10.1 2.5
PR13: bloated 80 1.29 0.60 22.5 1.2
PR14: hot flush 79 1.13 0.40 10.1 2.5
PR15: sore/enlarged nipples 80 1.24 0.56 18.8 1.2
PR16: leg/ankle swelling 80 1.23 0.48 20.0 1.2
PR17: weight loss 81 1.10 0.30  9.9 0.0
PR18: weight gain 81 1.22 0.45 21.0 0.0
PR19: less masculine 81 1.65 0.87 44.4 0.0
PR20: interest in sex 81 1.53 0.63 46.9 0.0
PR21: sexually active 80 1.19 0.45 16.3 1.2
PR22: sex enjoyable 14 1.93 0.62 78.6 82.7*
PR23: erection difficulty 14 2.07 0.83 78.6 82.7*
PR24: ejaculation difficulty 14 2.00 0.96 64.3 82.7*
PR25: uncomfortable  14 1.14 0.36 14.3 82.7*
*Conditional questions.
Table 3 Internal consistency, multi-item multi-method results of each scale of the EORTC QLQ-PR25
 
Cronbach’s α Item-own scale Item-other scale  Scaling success Scaling success
  correlation correlation*  rate
Urinary symptoms PR1–PR9 0.80 0.20–0.73 0.02–0.50 15/27  55.6
Bowel symptoms PR10–PR13 0.41 0.17–0.37 0.01–0.51  1/12  8.3
HT-related symptoms PR14–PR19 0.45 0.01–0.39 0.01–0.44  4/18  22.2
Sexual activity PR20–PR21 0.64 0.48 0.02–0.23  6/6 100.0
*The opposite value is displayed for negative correlations. HT = hormonal treatment.
and more hormonal-related symptoms than other 
groups; while those who underwent surgery had better 
physical and sexual activity than other groups (p < 0.01) 
(Table 6). For patients who had surgery, the extent of 
surgery was also related to QoL scores. Patients who un-
derwent radical prostatectomy had better physical, role, 
cognitive and sexual functioning, better global health 
and fewer fatigue symptoms; while patients who had no 
surgery had more constipation than other groups 
(p < 0.01) (Table 7). Patients who were off-treatment had 
better physical and role functioning, better global health, 
less fatigue, and fewer urinary and hormonal treatment-
related symptoms. Only the differences in physical func-
tioning and hormonal treatment-related symptoms 
were significant (p < 0.01) (Table 8).
4.  Discussion
In this study, we examined the internal consistency, 
multi-trait scaling, and known-groups comparison of the 
Taiwan Chinese version of the EORTC QLQ-C30 and 
QLQ-PR25 on 81 patients with prostate cancer cared for at 
the Department of Urology of National Taiwan University 
Hospital in Taipei. The acceptability of the questionnaires 
was high. The ages and educational levels of our patients 
were higher than that of the patients in the EORTC13 and 
Spanish14,15 studies.
The descriptive results of answers to the EORTC QLQ-
PR25 questions were as expected5 and correlated well 
to those of previous studies (in scales).13,15 The results 
of satisfactory internal consistency of urinary symptoms, 
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Table 4 Correlations between scales of the EORTC QLQ-C30 and QLQ-PR25
 QLQ-PR25 scales
QLQ-C30 scales 
Urinary symptoms Bowel symptoms
 Hormonal treatment- 
Sexual activity
   related symptoms
Functioning scales    
 Physical functioning −0.48* −0.46* −0.30† 0.18†
 Role functioning  −0.43* −0.50* −0.24† 0.26†
 Emotional functioning −0.51* −0.72‡ −0.39† 0.14†
 Cognitive functioning −0.47* −0.41* −0.31† 0.25†
 Social functioning −0.58* −0.54* −0.42* 0.13†
 Global health/QoL −0.50* −0.63* −0.32† 0.21†
Symptom scales    
 Fatigue 0.44* 0.46* 0.30† −0.23†
 Nausea and vomiting 0.08† 0.29† 0.41* −0.03†
 Pain 0.44* 0.47* 0.38† −0.04†
Single item scales    
 Dyspnea 0.40* 0.62* 0.45* −0.15†
 Insomnia 0.32† 0.42* 0.08† −0.13†
 Appetite loss 0.23† 0.33† 0.36† −0.17†
 Constipation 0.41* 0.35† 0.13† −0.24†
 Diarrhea 0.10† 0.37† 0.38† 0.03† 
 Financial difficulty 0.37† 0.54* 0.37† −0.12†
*0.40–0.70 (moderate correlation); †< 0.40 (weak correlation); ‡ > 0.70 (high correlation). QoL = quality of life.
Table 5  Quality of life scores of patients with different stages of disease
Scale
 Early disease Advanced disease Wilcoxon
 stages (I, II) (n = 59) stages (III, IV) (n = 22) two-sample test
Physical functioning 86.8 (16.7) 76.7 (23.0) 0.0057*
Role functioning 90.7 (19.6) 75.8 (33.2) 0.0380†
Emotional functioning 88.6 (13.2) 81.1 (26.0) 0.5515
Cognitive functioning 82.2 (16.6) 74.2 (26.1) 0.3168
Social functioning 87.0 (17.3) 68.9 (31.0) 0.0214†
Global health status 72.5 (18.9) 59.9 (25.5) 0.0612
Fatigue 16.6 (19.2) 37.9 (24.4) 0.0005*
Nausea and vomiting 0.3 (2.2) 3.0 (8.4) 0.0331†
Pain 8.2 (14.6) 21.2 (24.8) 0.0078*
Dyspnea 9.6 (15.2) 18.2 (28.6) 0.3540
Sleep 20.3 (22.3) 27.3 (33.6) 0.6672
Appetite 2.3 (8.5) 13.6 (26.6) 0.0142†
Constipation 13.0 (21.5) 19.7 (28.5) 0.3276
Diarrhea 10.2 (17.8) 12.1 (19.4) 0.7083
Financial difficulty 6.8 (14.9) 21.2 (28.3) 0.0133†
Urinary symptoms 20.9 (14.9) 26.2 (18.2) 0.2060
Bowel symptoms 4.7 (7.5) 9.5 (13.8) 0.2568
HT-related symptoms 7.3 (8.4) 12.6 (10.9) 0.0364†
Sexual activity 14.7 (17.0) 4.6 (7.6) 0.0111†
*p < 0.01; †p < 0.05. HT = hormonal treatment.
and unsatisfactory results in bowel symptoms and hor-
monal treatment-related symptoms were consistent with 
previous studies, and that of near-satisfactory sexual 
activity was close to that of previous studies.13,15 The low 
scaling success rate of urinary symptoms may be due to 
clinically plausible correlation between urinary symp-
toms and other symptoms. Our sexually active patients 
were too few to examine the properties of the last scale 
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Table 6 Quality of life scores among patients undergoing different treatments
Scale
 Surgery only Surgery and HT HT only Kruskal-Wallis
 (n = 29) (n = 39) (n = 12) test
Physical functioning 91.5 (18.7) 82.2 (17.9) 73.4 (17.9) 0.0004*
Role functioning 93.1 (20.2) 82.5 (27.8) 84.7 (24.1) 0.1354
Emotional functioning 81.1 (21.4) 86.8 (15.0) 84.7 (18.4) 0.6796
Cognitive functioning 79.3 (22.1) 82.1 (18.9) 75.0 (18.1) 0.4128
Social functioning 87.4 (23.4) 78.6 (22.3) 79.2 (24.8) 0.1268
Global health status 75.6 (21.5) 65.6 (19.8) 63.9 (25.5) 0.1238
Fatigue 16.1 (21.5) 24.5 (21.5) 32.4 (26.2) 0.0600
Nausea and vomiting 0.6 (3.1) 0.9 (3.7) 2.8 (9.6) 0.7846
Pain 9.8 (19.7) 11.5 (13.9) 18.1 (28.8) 0.5922
Dyspnea 9.2 (21.6) 12.0 (17.9) 19.4 (22.3) 0.1787
Sleep 26.4 (27.3) 19.7 (26.2) 22.2 (21.7) 0.4896
Appetite 6.9 (20.7) 4.3 (11.3) 5.6 (19.3) 0.9137
Constipation 10.3 (15.7) 11.1 (22.1) 36.1 (33.2) 0.0098*
Diarrhea 11.5 (20.5) 8.6 (14.8) 16.7 (22.5) 0.4997
Financial difficulty 9.2 (21.6) 10.3 (17.4) 16.7 (26.6) 0.5968
Urinary symptoms 18.1 (13.3) 22.6 (16.6) 31.6 (17.5) 0.0791
Bowel symptoms 4.3 (8.2) 6.1 (10.6) 9.0 (10.3) 0.2335
HT-related symptoms 5.0 (7.3) 10.4 (8.7) 13.4 (12.6) 0.0077*
Sexual activity 19.0 (18.8) 9.0 (12.6) 5.6 (10.9) 0.0147†
*p < 0.01; †p < 0.05. HT = hormonal treatment.
Table 7 Quality of life scores among patients undergoing different degrees of surgery
Scale
 Radical prostatectomy No surgery Partial prostatectomy Kruskal-Wallis
 (n = 50) (n = 12) (n = 19) test
Physical functioning 90.9 (10.8) 73.3 (18.6) 73.3 (27.2) 0.0003*
Role functioning 94.3 (12.4) 83.3 (24.7) 68.4 (38.0) 0.0054*
Emotional functioning 89.0 (13.9) 83.3 (18.6) 82.0 (25.2) 0.3766
Cognitive functioning 84.7 (17.1) 74.2 (18.8) 71.1 (25.1) 0.023†
Social functioning 85.7 (18.8) 72.3 (25.0) 74.6 (30.6) 0.4009
Global health status 74.8 (18.0) 63.6 (26.7) 56.6 (22.3) 0.0075*
Fatigue 14.7 (16.4) 32.3 (27.4) 38.0 (24.9) 0.0006*
Nausea and vomiting 1.0 (4.0) 3.0 (10.1) 0.0 (0.0) 0.4909
Pain 7.7 (10.8) 19.7 (29.6) 18.4 (24.8) 0.2071
Dyspnea 8.7 (14.8) 21.2 (22.5) 15.8 (28.0) 0.2252
Sleep 19.3 (22.4) 21.2 (22.5) 37.6 (34.2) 0.4434
Appetite 3.3 (10.1) 6.1 (20.1) 10.5 (25.0) 0.4077
Constipation 8.0 (15.9) 36.4 (34.8) 19.3 (25.6) 0.0020*
Diarrhea 9.3 (17.9) 15.2 (22.9) 12.3 (16.5) 0.5822
Financial difficulty 6.0 (12.9) 18.2 (27.3) 19.3 (27.9) 0.0694
Urinary symptoms 19.0 (13.0) 32.9 (17.7) 25.0 (19.5) 0.0552
Bowel symptoms 4.4 (7.6) 9.9 (10.4) 7.5 (13.3) 0.1019
HT-related symptoms 8.4 (9.2) 13.6 (13.2) 7.3 (6.2) 0.6024
Sexual activity 16.0 (16.8) 6.1 (11.2) 5.3 (11.2) 0.0048*
*p < 0.01; †p < 0.05. HT = hormonal treatment.
of sexual functioning. This is consistent with our study of 
breast cancer18 and the cultural characteristic that our 
patients avoid sex after having serious diseases such as 
cancer and focus much more on survival than sexual 
functioning.22 According to these findings, the scales of 
bowel symptoms and hormonal treatment-related symp-
toms may not be able to reflect the expected symptoms 
of patients and should be used with care. Most scales of 
the PR25 showed moderate to low correlation with that 
of the C30. But there were some scales that had high 
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Table 8 Quality of life scores between patients on- and off-treatment*
Scale
 No active treatment Active treatment Wilcoxon two-sample test
 within 6 mo (n = 26) within 6 mo (n = 55) t-approximation, two-sided p
Physical functioning 92.3 (10.1) 80.1 (21.0) 0.0024†
Role functioning 95.5 (10.1) 82.4 (28.4) 0.0403‡
Emotional functioning 89.7 (14.2) 85.0 (19.1) 0.1899
Cognitive functioning 82.7 (16.0) 78.8 (21.4) 0.5967
Social functioning 89.7 (17.1) 78.5 (24.8) 0.0612
Global health status 76.9 (17.7) 65.3 (22.3) 0.0481‡
Fatigue 12.8 (13.6) 26.9 (24.7) 0.0243‡
Nausea and vomiting 0.6 (3.3) 12.2 (5.4) 0.7841
Pain 6.4 (9.5) 14.2 (21.4) 0.1952
Dyspnea 6.4 (13.4) 14.6 (22.0) 0.1292
Sleep 20.5 (23.2) 23.0 (27.1) 0.9547
Appetite 2.6 (9.1) 6.7 (18.6) 0.4027
Constipation 10.2 (15.7) 17.0 (26.4) 0.3331
Diarrhea 9.0 (20.1) 11.5 (17.2) 0.3498
Financial difficulty 7.7 (14.3) 12.1 (22.6) 0.6470
Urinary symptoms 16.0 (11.2) 25.3 (17.0) 0.0185‡
Bowel symptoms 3.5 (6.3) 7.1 (10.8) 0.1853
HT-related symptoms 4.7 (7.3) 10.7 (9.6) 0.0056‡
Sexual activity 9.4 (13.1) 7.9 (15.3) 0.0511
*Reproduced from Reference 4; †p < 0.01; ‡p < 0.05. HT = hormonal treatment.
correlation with scales of the core questionnaire. This is 
different from the results of the validation study of the 
EORTC13 but close to the Spanish study.15
The results of known-groups comparison showed a 
better performance of the core questionnaire (C30) than 
the newly developed PR25. The performance of the C30 
was consistent with the result of group comparison in 
the Spanish study.14 Regarding the PR25, the scale of uri-
nary symptoms could differentiate between on- and off-
treatment; the scale of hormonal treatment-related 
symptoms could differentiate among stages, treatment 
methods, and on- and off-treatment; and the scale of 
sexual activity could differentiate among stages, treat-
ments, and extent of surgery. Bowel symptoms did not 
differ in any of the four clinical conditions. These results 
were less good than those of previous validation studies 
using treatment intention and Karnofsky performance 
score.13,15
This study had some limitations. The sample size was 
small, but the problem could be resolved with non-para-
metric statistical methods. We did not collect Karnofsky 
performance scores. But data of clinical conditions were 
enough for known-groups comparison. We only collected 
data at one time-point and did not conduct test–retest 
and change over time comparison. The number of sexu-
ally active patients was too small to do any tests for the 
specific scale of sexual functioning. These issues may be 
included in future studies. Prostate cancer is increasing 
rapidly in Taiwan,3,4 and the instrument will be useful 
in the assessment of treatment effectiveness through 
patients’ QoL.
In conclusion, the Taiwan Chinese version of the 
EORTC QLQ-PR25 is acceptable to Taiwanese patients 
with prostate cancer. However, the scale structure of this 
module and the differential ability of the scale of bowel 
symptoms were not very satisfactory. The clinical valid-
ity of scales for different clinical conditions was accepta-
ble but less so than those of the EORTC QLQ-C30. Some 
questions may need to be modified to reflect Taiwanese 
patients’ problems more accurately.
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